Patents by Inventor Anton Dobrin

Anton Dobrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133802
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing immune responses toward tumor and pathogen antigens. It relates to fusion polypeptide that can be expressed in cells (e.g., immunoresponsive cells comprising an antigen-recognizing receptor) to improve the activity and/or efficiency of the cells. In certain embodiments, the fusion polypeptide comprises an extracellular domain and a transmembrane domain of a co-stimulatory ligand, and an intracellular domain of a co-stimulatory molecule.
    Type: Application
    Filed: January 19, 2022
    Publication date: May 5, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Mohamad Hamieh, Anton Dobrin
  • Publication number: 20220031754
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 3, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • Patent number: 11229669
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 25, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • Publication number: 20210030804
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: October 20, 2020
    Publication date: February 4, 2021
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • Publication number: 20200368283
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Application
    Filed: August 11, 2020
    Publication date: November 26, 2020
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin